vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and ANI PHARMACEUTICALS INC (ANIP). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). Andersons, Inc. runs the higher net margin — 20.5% vs 11.1%, a 9.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -2.4%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-77.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ANDE vs ANIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $247.1M |
| Net Profit | $67.4M | $27.5M |
| Gross Margin | 70.3% | — |
| Operating Margin | 26.6% | 14.1% |
| Net Margin | 20.5% | 11.1% |
| Revenue YoY | -2.4% | 29.6% |
| Net Profit YoY | 49.6% | 367.5% |
| EPS (diluted) | — | $1.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $247.1M | ||
| Q3 25 | $295.8M | $227.8M | ||
| Q2 25 | $535.0M | $211.4M | ||
| Q1 25 | $370.8M | $197.1M | ||
| Q4 24 | $337.5M | $190.6M | ||
| Q3 24 | $231.9M | $148.3M | ||
| Q2 24 | $492.5M | $138.0M | ||
| Q1 24 | $341.4M | $137.4M |
| Q4 25 | $67.4M | $27.5M | ||
| Q3 25 | $20.1M | $26.6M | ||
| Q2 25 | $7.9M | $8.5M | ||
| Q1 25 | $284.0K | $15.7M | ||
| Q4 24 | $45.1M | $-10.3M | ||
| Q3 24 | $27.4M | $-24.2M | ||
| Q2 24 | $36.0M | $-2.3M | ||
| Q1 24 | $5.6M | $18.2M |
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 37.6% | — |
| Q4 25 | 26.6% | 14.1% | ||
| Q3 25 | 8.7% | 15.9% | ||
| Q2 25 | 4.6% | 6.6% | ||
| Q1 25 | 0.9% | 13.3% | ||
| Q4 24 | 19.9% | -2.3% | ||
| Q3 24 | 26.8% | -13.8% | ||
| Q2 24 | 11.6% | 3.7% | ||
| Q1 24 | 4.1% | 14.8% |
| Q4 25 | 20.5% | 11.1% | ||
| Q3 25 | 6.8% | 11.7% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 0.1% | 8.0% | ||
| Q4 24 | 13.4% | -5.4% | ||
| Q3 24 | 11.8% | -16.3% | ||
| Q2 24 | 7.3% | -1.7% | ||
| Q1 24 | 1.6% | 13.2% |
| Q4 25 | — | $1.14 | ||
| Q3 25 | $0.59 | $1.13 | ||
| Q2 25 | $0.23 | $0.36 | ||
| Q1 25 | $0.01 | $0.69 | ||
| Q4 24 | $1.31 | $-0.45 | ||
| Q3 24 | $0.80 | $-1.27 | ||
| Q2 24 | $1.05 | $-0.14 | ||
| Q1 24 | $0.16 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $285.6M |
| Total DebtLower is stronger | $560.0M | — |
| Stockholders' EquityBook value | $1.2B | $540.7M |
| Total Assets | $3.7B | $1.4B |
| Debt / EquityLower = less leverage | 0.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $285.6M | ||
| Q3 25 | — | $262.6M | ||
| Q2 25 | — | $217.8M | ||
| Q1 25 | — | $149.8M | ||
| Q4 24 | $561.8M | $144.9M | ||
| Q3 24 | — | $145.0M | ||
| Q2 24 | — | $240.1M | ||
| Q1 24 | — | $228.6M |
| Q4 25 | $560.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $540.7M | ||
| Q3 25 | $1.2B | $505.8M | ||
| Q2 25 | $1.4B | $436.8M | ||
| Q1 25 | $1.4B | $418.6M | ||
| Q4 24 | $1.4B | $403.7M | ||
| Q3 24 | $1.3B | $405.9M | ||
| Q2 24 | $1.3B | $455.8M | ||
| Q1 24 | $1.3B | $452.0M |
| Q4 25 | $3.7B | $1.4B | ||
| Q3 25 | $3.3B | $1.4B | ||
| Q2 25 | $3.4B | $1.3B | ||
| Q1 25 | $3.8B | $1.3B | ||
| Q4 24 | $4.1B | $1.3B | ||
| Q3 24 | $3.4B | $1.3B | ||
| Q2 24 | $3.3B | $920.8M | ||
| Q1 24 | $3.3B | $914.5M |
| Q4 25 | 0.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $30.4M |
| Free Cash FlowOCF − Capex | $-77.1M | $29.1M |
| FCF MarginFCF / Revenue | -23.4% | 11.8% |
| Capex IntensityCapex / Revenue | 21.5% | 0.5% |
| Cash ConversionOCF / Net Profit | -0.09× | 1.10× |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | $171.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $30.4M | ||
| Q3 25 | $233.9M | $44.1M | ||
| Q2 25 | $299.3M | $75.8M | ||
| Q1 25 | $-350.0M | $35.0M | ||
| Q4 24 | $268.8M | $15.9M | ||
| Q3 24 | $-2.1M | $12.5M | ||
| Q2 24 | $304.4M | $17.4M | ||
| Q1 24 | $-239.6M | $18.3M |
| Q4 25 | $-77.1M | $29.1M | ||
| Q3 25 | $167.0M | $38.0M | ||
| Q2 25 | $250.5M | $71.8M | ||
| Q1 25 | $-396.6M | $32.5M | ||
| Q4 24 | $212.9M | $13.5M | ||
| Q3 24 | $-40.0M | $7.7M | ||
| Q2 24 | $275.8M | $13.0M | ||
| Q1 24 | $-266.4M | $13.7M |
| Q4 25 | -23.4% | 11.8% | ||
| Q3 25 | 56.5% | 16.7% | ||
| Q2 25 | 46.8% | 34.0% | ||
| Q1 25 | -106.9% | 16.5% | ||
| Q4 24 | 63.1% | 7.1% | ||
| Q3 24 | -17.2% | 5.2% | ||
| Q2 24 | 56.0% | 9.4% | ||
| Q1 24 | -78.0% | 10.0% |
| Q4 25 | 21.5% | 0.5% | ||
| Q3 25 | 22.6% | 2.7% | ||
| Q2 25 | 9.1% | 1.9% | ||
| Q1 25 | 12.6% | 1.3% | ||
| Q4 24 | 16.6% | 1.3% | ||
| Q3 24 | 16.3% | 3.2% | ||
| Q2 24 | 5.8% | 3.2% | ||
| Q1 24 | 7.8% | 3.3% |
| Q4 25 | -0.09× | 1.10× | ||
| Q3 25 | 11.61× | 1.66× | ||
| Q2 25 | 38.10× | 8.87× | ||
| Q1 25 | -1232.46× | 2.23× | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
